Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study
- 14 October 2023
- journal article
- research article
- Published by Springer Nature in Pediatric Radiology
- Vol. 53 (13) , 2622-2632
Abstract
Background Ferumoxytol is becoming more widely used as an off-label blood-pool contrast agent for MR angiography (MRA) and four-dimensional (4D) flow imaging in pediatric cardiovascular disease. Brand and generic versions of ferumoxytol are available with no information on relative efficacy as a contrast agent and safety profiles. Objective This study evaluates patient safety and image quality of comparable dosages of generic ferumoxytol (GF) versus brand ferumoxytol (BF) with the following hypotheses: (1) Reducing the contrast dosage from 3 to 2 mg/kg will not affect imaging quality and diagnostic accuracy of MRA and four-dimensional 4D flow. (2) GF and BF have similar image quality. (3) GF and BF have similar patient safety profiles. Materials and methods In an IRB-approved retrospective study, changes in vitals/clinical status between baseline, during infusion, and 30 min post-infusion were analyzed in 3 groups: group 1 (3 mg/kg BF, 216 patients, age: 19.29 ± 11.71 years ranging from 2 months to 62 years), group 2 (2 mg/kg BF, 47 patients, age: 15.35 ± 8.56 years ranging from 10 days to 41 years), and group 3 (2 mg/kg GF, 127 patients, age: 17.16 ± 12.18 years ranging from 6 days to 58 years). Both pediatric and adult patients with congenital heart disease (CHD) indications were included within the study. Adverse reactions were classified as mild, moderate, or severe. Quantitative analysis of MR image quality was performed with signal-to-noise ratio (SNR) on MRA and velocity-to-noise ratio (VNR) on 4D flow. Qualitative grading of imaging features was performed by 2 experienced observers. Two-way analysis of variance (ANOVA) and chi-square tests were used for comparison with a P value of ≤ 0.05 used for significance. Results No statistical difference was found in clinical status and vital signs (P>0.05). No severe reactions were reported. 7.9% of GF patients experienced an adverse reaction compared to 2.3% with 3 mg/kg BF and 8.4% with 2 mg/kg BF. There was no statistical difference in SNR between the 3 groups (P>0.05). For 4D flow, 2 mg/kg GF demonstrated an increase in VNR compared to 2 mg/kg BF (P = 0.005). The qualitative scores for MRA and 4D flow were high (≥ 3) across all 3 groups. Conclusions No significant difference was identified between 2 mg/kg GF and BF in terms of safety profile and image quality. Given the small sample size of this study, further studies are required to confirm these results. Graphical AbstractKeywords
This publication has 20 references indexed in Scilit:
- Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in childrenPediatric Radiology, 2014
- Hypersensitivity reactions to intravenous iron: guidance for risk minimization and managementHaematologica, 2014
- Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applicationsCurrent Opinion in Pharmacology, 2014
- A Phase III, randomized, open‐label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapyAmerican Journal of Hematology, 2014
- MRI Assessment of Hepatic Iron Clearance Rates After USPIO Administration in Healthy AdultsInvestigative Radiology, 2012
- Variable velocity encoding in a three‐dimensional, three‐directional phase contrast sequence: Evaluation in phantom and volunteersJournal of Magnetic Resonance Imaging, 2012
- Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?Journal of Blood Medicine, 2012
- Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney diseaseJournal Of Nephrology, 2011
- Physicochemical properties of ferumoxytol, a new intravenous iron preparationEuropean Journal of Clinical Investigation, 2009
- Recent advances in iron oxide nanocrystal technology for medical imaging☆Advanced Drug Delivery Reviews, 2006